Kazia Therapeutics Limited (KZIA) P/E Ratio History
Deep ValueTrading at -1.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2002–2003
Loading P/E history...
P/E Ratio Analysis
As of June 13, 2026, Kazia Therapeutics Limited (KZIA) trades at a price-to-earnings ratio of -1.1x, with a stock price of $14.28 and trailing twelve-month earnings per share of $-30.37.
The current P/E is 114% below its 5-year average of 7.5x. Over the past five years, KZIA's P/E has ranged from a low of 7.4x to a high of 7.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, KZIA trades at a 105% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 183.0x.
Relative to the broader market, KZIA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KZIA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KZIA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
KZIA P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 17.9Lowest | -Best | +1747%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
KZIA Historical P/E Data (2002–2003)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2003 Q4 | Jun 30 2003 | $5764.95 | $755.90 | 7.6x | +1% |
| FY2002 Q4 | Jun 30 2002 | $2056.55 | $276.90 | 7.4x | -1% |
Average P/E for displayed period: 7.5x
What if you invested $1,000 in KZIA back in 2002?
Total return with dividends reinvested · 24+ years of data
Calculate ReturnsHow much would $100/month in KZIA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KZIA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKZIA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowKZIA — Frequently Asked Questions
Quick answers to the most common questions about buying KZIA stock.
What is KZIA's P/E ratio?
Kazia Therapeutics Limited (KZIA) trailing twelve-month P/E ratio is -1.1x, based on TTM diluted EPS of $-30.37. The 5-year average P/E is 7.5x and the historical range spans 7.4x to 7.6x.
Is KZIA stock overvalued or undervalued?
KZIA trades at -1.1x P/E, below its 5-year average of 7.5x. At the 0th percentile of its historical range (7.4x–7.6x), the stock is priced at a discount to its own history.
Is KZIA stock expensive?
No, KZIA is not expensive on a historical basis. The current P/E of -1.1x is below the 5-year average of 7.5x and sits at the 0th percentile of its valuation range.
What is KZIA's historical P/E range?
Over the past 5 years, KZIA's P/E ratio has ranged from 7.4x to 7.6x, with a median of 7.6x and an average of 7.5x. The current P/E of -1.1x places the stock at the 0th percentile of this range. Full historical data spans 2002–2003.
How does KZIA's P/E compare to the S&P 500?
KZIA trades at -1.1x P/E versus the S&P 500 median of 25.1x. The 104% discount to the market suggests lower growth expectations or perceived higher risk.
How does KZIA's valuation compare to Healthcare peers?
Kazia Therapeutics Limited P/E of -1.1x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is KZIA's PEG ratio?
KZIA PEG ratio is N/A, based on a P/E of -1.1x and EPS growth of 65.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is KZIA's earnings yield?
KZIA earnings yield is N/A, the inverse of its -1.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.